Blog
RSS FeedPosted by Michael Wonder on 19 Mar 2025
Linzagolix choline in endometriosis: comparative data are lacking
18 March 2025 - There are no comparative studies with established active ingredients in endometriosis; placebo comparisons are unsuitable for assessing ...
Posted by Michael Wonder on 01 Feb 2025
High quality evidence for the treatment of very rare diseases: IQWiG is involved in the EU project RealiseD
29 January 2025 - Developing clinical studies for good evidence on very rare diseases in order to arrive at effective therapies ...
Posted by Michael Wonder on 06 Jan 2025
Enfortumab vedotin plus pembrolizumab in advanced bladder cancer: evidence of a significant additional benefit
2 January 2025 - Patients for whom cisplatin-based therapy is unsuitable live significantly longer with the new combination of active ingredients ...
Posted by Michael Wonder on 16 Dec 2024
Findings from the EUnetHTA 21 project for EU-HTA from 2025
12 December 2024 - The results from EUnetHTA 21 provide insights for future cooperation in EU-HTA: participants from IQWiG and ...
Posted by Michael Wonder on 05 Dec 2024
Results of health technology assessments of orphan drugs in Germany—lack of added benefit, evidence gaps, and persisting unmet medical needs
3 December 2024 - The number of orphan drug approvals has increased sharply in Europe. In Germany, all orphan drugs are ...
Posted by Michael Wonder on 20 Oct 2024
Prostate cancer: significant additional benefit for PSMA diagnostics with gozetotide
15 October 2024 - Because of the direct link between diagnosis and therapy, the data from the early benefit assessment ...
Posted by Michael Wonder on 03 Sep 2024
Vadadustat for symptomatic anaemia due to chronic kidney disease: missed opportunity
2 September 2024 - In the two manufacturer studies, important patient-relevant outcomes were not recorded. ...
Posted by Michael Wonder on 12 Aug 2024
Changes in revenues associated with antimicrobial reimbursement reforms in Germany
10 August 2024 - Policy declarations from the G7 and other high-level meetings call for increased incentives for antimicrobial research and ...
Posted by Michael Wonder on 03 Jul 2024
Gadopiclenol as an MRI contrast agent: first benefit assessment of a diagnostic agent
1 July 2024 - For the first time, IQWiG has evaluated a drug that is a diagnostic agent within the ...
Posted by Michael Wonder on 02 Apr 2024
Polatuzumab vedotin in untreated diffuse large B-cell lymphoma: one step forward, two steps back
2 April 2024 - Roche designed its trial for both approval and health technology assessments but the analyses planned for ...
Posted by Michael Wonder on 04 Mar 2024
Tebentafusp in uveal melanoma: indication of a considerable additional benefit
1 March 2024 - Patients with inoperable or metastatic uveal melanoma survive longer with the new therapy than with other therapy ...
Posted by Michael Wonder on 02 Mar 2024
Patisiran sodium in hereditary transthyretin amyloidosis: less benefit than vutrisiran
1 March 2024 - In 2023, IQWiG found an additional benefit of vutrisiran compared to patisiran sodium based on a study. ...
Posted by Michael Wonder on 01 Feb 2024
Significant additional benefit of mavacamten in hypertrophic obstructive cardiomyopathy
1 February 2024 - In a dossier assessment in 2023, an additional benefit could not yet be proven due to unclear ...
Posted by Michael Wonder on 18 Jan 2024
New orphan drug for a sub-type of acute myeloid leukaemia: G-BA sees significant additional benefit
18 January 2024 - Since July 2023, there has been one in Germany for patients who suffer from acute myeloid leukaemia ...
Posted by Michael Wonder on 04 Dec 2023
Vosoritide in achondroplasia: indication of an additional clinical benefit for children aged two and over
1 December 2023 - Two small RCTs with children of different ages together make it possible to make one statement: the ...